Today it was reported that the Interim President & CEO of Idexx Laboratories (IDXX), Jay Mazelsky, exercised options to buy 11,358 IDXX shares at $47.20 a share, for a total transaction value of $536.1K. The options were close to expired and Jay Mazelsky retained stocks.
This recent transaction increases Jay Mazelsky’s holding in the company by 80.46% to a total of $9.54 million. In addition to Jay Mazelsky, 4 other IDXX executives reported Buy trades in the last month.
See today’s analyst top recommended stocks >>
Based on Idexx Laboratories’ latest earnings report for the quarter ending June 30, the company posted quarterly revenue of $620 million and quarterly net profit of $126 million. In comparison, last year the company earned revenue of $581 million and had a net profit of $109 million. The Company has a Price to Book ratio of 140.4461. IDXX’s market cap is $23.72B and the company has a P/E ratio of 60.13.
Starting in August 2018, IDXX received 16 Buy ratings in a row. Four different firms, including Merrill Lynch and Canaccord Genuity, currently also have a Buy rating on the stock. Based on 4 analyst ratings, the analyst consensus is Strong Buy with an average price target of $289.00, reflecting a 3.6% upside.
In the last 30 days, insiders have sold $14.96M worth of IDXX shares and purchased $636K worth of IDXX shares. The insider sentiment on Idexx Laboratories has been negative according to 71 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.
Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
IDEXX Laboratories, Inc. engages in the development, manufacture, and distribution of products and services for the animal veterinary, livestock and poultry, dairy and water testing markets. It operates through the following segments: Companion Animal Group; Water; Livestock, Poultry, and Dairy; and Other.
